Stereo- and regioselectivity of hepatic oxidation in man - Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation

European Journal of Clinical Pharmacology

Volumn 31, Issue 3, 1986, Pages 313-318

  Dayer, P ^a   Leemann, T ^a   Kupfer A ^b   Kronbach, T ^c   Meyer, U A ^c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

bufuralol; debrisoquine sparteine phenotype; drug metabolism; healthy volunteers; hepatic oxidation; metabolites; polymorphism; stereo and regioselectivity

Indexed keywords

1' HYDROXYBUFURALOL; BUFURALOL; CYTOCHROME P450; DEBRISOQUINE; SPARTEINE; UNCLASSIFIED DRUG;

DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME DEFICIENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; STEREOCHEMISTRY; VOLUNTEER;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEBRISOQUIN; ETHANOLAMINES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; ISOQUINOLINES; KINETICS; MALE; MICROSOMES, LIVER; OXIDATION-REDUCTION; PHENOTYPE; POLYMORPHISM, GENETIC; SPARTEINE; STEREOISOMERISM;

EID: 0022869718     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00981130     Document Type: Article

References (25)

1. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology
2. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man
3. Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activities
4. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver
5. Betablockers and drug oxidation status
6. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolizers
7. The genetic control of bufuralol metabolism in man
8. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents
9. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine/sparteine type polymorphism): Increased Michaelis constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers
10. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol
11. Steric configuration and polymorphic oxidation of lipophilic beta-adrenoceptor blocking agents: In vivo — in vitro correlations
12. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: Influence of genetic status on behavior of atenolol, bopindolol and metoprolol
13. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
14. Defective oxidation of drugs: Pharmacokinetic and therapeutic implications
15. Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection
16. The metabolism of bufuralol — Urinary metabolite: Profiles in rat, dog and man
17. Kinetics and metabolism of (+)-, (−) and (+/−)-bufuralol
18. The influence of stereochemical factors on drug disposition
19. Direct determination of R- and S-metoprolol in biological fluids, by ion-pair-HPLC
20. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolisers
21. The polymorphic oxidation of β-adrenoceptor antagonists — Clinical pharmacokinetic consideration
22. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation
23. Bufuralol metabolism in human liver: A sensitive probe for the debrisoquine-type of polymorphism of drug oxidation
24. The molecular mechanisms of common polymorphisms of drug oxidation — Evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation
25. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative 0-demethylation with debrisoquine hydroxylation